Not so sweet!!: Posttransplant diabetes ‒ An update for the nephrologist

The landscape of posttransplant diabetes mellitus (PTDM) has transformed drastically over the past 20 years witnessing changes ranging from the definition and pathophysiology to the use of newer agents such as sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in the treatment of PTDM. Its unique pathophysiology leads to a different timescale for the development of cardiovascular events when compared with type 1 and type 2 diabetes. This review provides an up-to-date synopsis of the definition, pathophysiology, prevention, and treatment aspects of PTDM for the nephrologist.